Receptor TrK
Os inibidores dos receptores Trk têm como alvo as quinases receptoras da tropomiosina (Trk), uma família de tirosina quinases receptoras que desempenham um papel significativo no desenvolvimento e função do sistema nervoso. Os receptores Trk estão envolvidos na sinalização de neurotrofinas, essencial para a sobrevivência, diferenciação e crescimento dos neurônios. A desregulação da sinalização Trk está associada a distúrbios neurológicos e certos tipos de câncer. Na CymitQuimica, oferecemos inibidores dos receptores Trk para apoiar sua pesquisa em neurobiologia, oncologia e doenças neurodegenerativas.
Foram encontrados 59 produtos de "Receptor TrK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GNF-5837
CAS:<p>GNF-5837 is a specific, and orally bioavailable pan-TRK inhibitor for TrkA/TrkB (IC50: 8/12 nM).</p>Fórmula:C28H21F4N5O2Pureza:97.26% - 98.08%Cor e Forma:SolidPeso molecular:535.49DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8GW 441756
CAS:<p>GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.</p>Fórmula:C17H13N3OPureza:97.73% - 99.8%Cor e Forma:SolidPeso molecular:275.3Tyrphostin AG 879
CAS:<p>Tyrphostin AG 879 (AG 879) effectively inhibits HER2/ErbB2 (IC50: 1 μM), 100- and 500-fold higher selective to ErbB2 than EGFR and PDGFR.</p>Fórmula:C18H24N2OSPureza:99.05%Cor e Forma:SolidPeso molecular:316.46Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Fórmula:C33H29F2N5O4SPureza:98.9% - 99.85%Cor e Forma:SolidPeso molecular:629.68LM22B-10
CAS:<p>LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor and can induce TrkB, TrkC, ERK and AKT activation in vitro and in vivo.</p>Fórmula:C27H33ClN2O4Pureza:98.18%Cor e Forma:SolidPeso molecular:485.01Larotrectinib
CAS:<p>Larotrectinib (LOXO-101) is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).</p>Fórmula:C21H22F2N6O2Pureza:99.15% - >99.99%Cor e Forma:SolidPeso molecular:428.44CH7057288
CAS:<p>CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM, 7.8 nM and 5.1 nM for TRKA, TRKB and TRKC, respectively.</p>Fórmula:C32H31N3O5SPureza:99.92%Cor e Forma:SolidPeso molecular:569.67Larotrectinib sulfate
CAS:<p>Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).</p>Fórmula:C21H22F2N6O2·H2O4SPureza:98.62% - 99.76%Cor e Forma:SolidPeso molecular:526.51Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Fórmula:C18H18FN5O2Pureza:99.92% - >99.99%Cor e Forma:SolidPeso molecular:355.377,8-Dihydroxyflavone
CAS:<p>7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.</p>Fórmula:C15H10O4Pureza:98.48% - 99.81%Cor e Forma:SolidPeso molecular:254.24Frunevetmab
CAS:<p>Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).</p>Pureza:95% - 95%Cor e Forma:LiquidFasinumab
CAS:<p>Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.</p>Pureza:95%Cor e Forma:LiquidFulranumab
CAS:<p>Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.</p>Pureza:95%Cor e Forma:LiquidTanezumab
CAS:<p>Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.</p>Pureza:95%Cor e Forma:LiquidBMS-754807
CAS:<p>BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.</p>Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49Protein kinase inhibitor 5
CAS:<p>Protein kinase inhibitor 5 is a potent inhibitor of TRK-A, demonstrating an IC50 of 1.8 nM, and effectively suppresses cell viability [1].</p>Fórmula:C29H31F2N7OPureza:98%Cor e Forma:SolidPeso molecular:531.6Tavilermide
CAS:<p>Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.</p>Fórmula:C24H32N6O11Pureza:98.98%Cor e Forma:SolidPeso molecular:580.54TrkA-IN-1
CAS:<p>TrkA-IN-1 is a potent and selective inhibitor of Tropomyosin-related kinase A (TrkA) (IC50: 99 nM in a cell-based assay) with analgesic activity.</p>Fórmula:C25H20N4OPureza:98%Cor e Forma:SolidPeso molecular:392.45Paltimatrectinib
CAS:<p>Paltimatrectinib (PBI-200) is a tyrosine kinase inhibitor with anticancer activity, and is used in the study of bladder, breast, and colorectal cancers.</p>Fórmula:C20H15F5N6Pureza:99.96%Cor e Forma:SolidPeso molecular:434.37
